Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation

References

• Rolston KV. Infections in patients with acute leukemia. 1st ed. Berlin, Heidelberg: Springer; 2015. p. 3–23.
   Google Scholar
• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–237.
   PubMed Web of Science ®Google Scholar
• Li Y, Klippel Z, Shih X, et al. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Support Care Cancer. 2016;24:4377–4383.
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology and infectious diseases society of America clinical practice guideline update. J Clin Oncol. 2018;36:1443–1453.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.
   PubMed Web of Science ®Google Scholar
• Heinz WJ, Buchheidt D, Christopeit M, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and medical oncology (DGHO). Ann Hematol. 2017;96:1775–1792.
   PubMed Web of Science ®Google Scholar
• Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579–587.
   PubMed Web of Science ®Google Scholar
• Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010;19:231–237.
   PubMed Web of Science ®Google Scholar
• Cullen MH, Billingham LJ, Gaunt CH, et al. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol. 2007;25:4821–4828.
   PubMed Web of Science ®Google Scholar
• Buchheidt D, Böhme A, Cornely OA, et al. Diagnosis and treatment of documented infections in neutropenic patients–recommendations of the infectious diseases working party (AGIHO) of the German society of hematology and oncology (DGHO). Ann Hematol. 2003;82(Suppl 2):S127–S132.
   Google Scholar
• Jackson K, Mollee P, Morris K, et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. Leuk Lymphoma. 2014;55:97–104.
   PubMed Web of Science ®Google Scholar
• Link H, Maschmeyer G, Meyer P, et al. Interventional antimicrobial therapy in febrile neutropenic patients. Study group of the Paul Ehrlich society for chemotherapy. Ann Hematol. 1994;69:231–243.
   PubMed Web of Science ®Google Scholar
• Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signalling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24:S53–S70.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Teschner D, Schalk E. Febrile Neutropenie – Risikofaktoren, Prophylaxe und Algorithmen zur antimikrobiellen Therapie. J Onkologie. 2018;5:25–33.
   Google Scholar
• Marchetti O, Calandra T. Infections in neutropenic cancer patients. Lancet. 2002;359:723–725.
   PubMed Web of Science ®Google Scholar
• Rönkkö R, Juutilainen A, Koivula I, et al. Changes in the microbiological epidemiology of febrile neutropenia in autologous stem cell transplant recipients. Infect Dis (Lond). 2018;50:436–442.
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987.
   PubMed Web of Science ®Google Scholar
• Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–998.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.
   PubMedGoogle Scholar
• Gouliouris T, Warne B, Cartwright EJP, et al. Duration of exposure to multiple antibiotics is associated with increased risk of VRE bacteraemia: a nested case-control study. J Antimicrob Chemother. 2018;73:1692–1699.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–e93.
   Web of Science ®Google Scholar
• Zimmer A, Freifeld A. When to use prophylactic antibiotics in neutropenic patients. Oncology (Williston Park). 2016;30:838–840.
   PubMed Web of Science ®Google Scholar
• Neumann S, Krause SW, Maschmeyer G, et al. Primary prophylaxis of bacterial infections and pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and oncology (DGHO). Ann Hematol. 2013;92:433–442.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Böhme A, Cornely OA, et al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the infectious diseases working party AGIHO of the German society for haematology and medical oncology (DGHO). Ann Oncol. 2014;25:1709–1718.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–3212.
   PubMed Web of Science ®Google Scholar
• Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO). Ann Hematol. 2018;97:197–207.
   PubMed Web of Science ®Google Scholar
• Sandherr M, Hentrich M, von Lilienfeld-Toal M, et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies–update of the guidelines of the infectious diseases working party (AGIHO) of the German society for hematology and medical oncology (DGHO). Ann Hematol. 2015;94:1441–1450.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Schmidt-Hieber M, Bertz H, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016;95:1435–1455.
   PubMed Web of Science ®Google Scholar
• Ritchie S, Palmer S, Ellis-Pegler R. High-risk febrile neutropenia in Auckland 2003–2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy. Intern Med J. 2007;37:26–31.
   PubMed Web of Science ®Google Scholar
• Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents. 2008;32(Suppl 1):S30–S33.
   PubMedGoogle Scholar
• Heriot GS, Tam C, Waters M-J. Factors predicting the identification of new organisms in follow-up blood cultures drawn during episodes of neutropenic sepsis. Br J Haematol. 2017;182(3).
   PubMed Web of Science ®Google Scholar
• Kimura SI, Gomyo A, Hayakawa J, et al. Clinical significance of repeat blood cultures during febrile neutropenia in adult acute myeloid leukaemia patients undergoing intensive chemotherapy. Infect Dis (Lond). 2017;49:748–757.
   PubMed Web of Science ®Google Scholar
• Greco R, Barbanti MC, Mancini N, et al. Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. Bone Marrow Transplant. 2018;53:410–416.
   PubMed Web of Science ®Google Scholar
• Penack O, Becker C, Buchheidt D, et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the infectious diseases working party of the german society of hematology and medical oncology (AGIHO). Ann Hematol. 2014;93:1083–1095.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596.
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–810.
   PubMed Web of Science ®Google Scholar
• Kim M, Ahn S, Kim WY, et al. Predictive performance of the quick sequential organ failure assessment score as a screening tool for sepsis, mortality, and intensive care unit admission in patients with febrile neutropenia. Support Care Cancer. 2017;25:1557–1562.
   PubMed Web of Science ®Google Scholar
• Thursky K, Lingaratnam S, Jayarajan J, et al. Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs. BMJ Open Qual. 2018;7(3):e000355.
   PubMedGoogle Scholar
• Wu CW, Wu JY, Chen CK, et al. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer. 2015;23:2863–2872.
   PubMed Web of Science ®Google Scholar
• Sbrana A, Torchio M, Comolli G, et al. Use of procalcitonin in clinical oncology: a literature review. New Microbiol. 2016;39:174–180.
   PubMed Web of Science ®Google Scholar
• Michel CS, Teschner D, Wagner EM, et al. Diagnostic value of sTREM-1, IL-8, PCT, and CRP in febrile neutropenia after autologous stem cell transplantation. Ann Hematol. 2017;96:2095–2101.
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Carratalà J, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and medical oncology (DGHO). Ann Oncol. 2015;26:21–33.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Silling G, Schalk E, et al. CNS infections in patients with hematological disorders (including allogeneic stem cell transplantation) guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and medical oncology (DGHO). Ann Oncol. 2016;27:1207–1225.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Bierwirth J, Buchheidt D, et al. Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and medical oncology (DGHO). Ann Hematol. 2018;97:31–49.
   PubMed Web of Science ®Google Scholar
• de Naurois J, Novitzky-Basso I, Mj G, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21(Suppl 5):v252–v256.
   PubMedGoogle Scholar
• Patsios D, Maimon N, Chung T, et al. Chest low-dose computed tomography in neutropenic acute myeloid leukaemia patients. Respir Med. 2010;104:600–605.
   PubMed Web of Science ®Google Scholar
• Gerritsen MG, Willemink MJ, Pompe E, et al. Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography. PLoS ONE. 2017;12:e0172256.
   PubMed Web of Science ®Google Scholar
• Oude Nijhuis CSM, Gietema JA, Vellenga E, et al. Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. Eur J Cancer. 2003;39:2495–2498.
   PubMed Web of Science ®Google Scholar
• Vallipuram J, Dhalla S, Bell CM, et al. Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma. 2017;58:834–841.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98:1826–1835.
   PubMed Web of Science ®Google Scholar
• Balletto E, Mikulska M. Bacterial infections in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis. 2015;7:e2015045.
   PubMed Web of Science ®Google Scholar
• Tatarelli P, Mikulska M. Multidrug-resistant bacteria in hematology patients: emerging threats. Future Microbiol. 2016;11:767–780.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Gallaher A, Jain R, et al. Infusion-compatible antibiotic formulations for rapid administration to improve outcomes in cancer outpatients with severe sepsis and septic shock: the sepsis STAT pack. J Natl Compr Canc Netw. 2017;15:457–464.
   PubMed Web of Science ®Google Scholar
• Horita N, Shibata Y, Watanabe H, et al. Comparison of antipseudomonal β-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect. 2017;23:723–729.
   PubMed Web of Science ®Google Scholar
• Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010;11:CD005197.
   Google Scholar
• Averbuch D, Orasch C, Mikulska M, et al. Re: “Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network metaanalysis” by Horita et al. Clin Microbiol Infect. 2018;24:662–663.
   PubMed Web of Science ®Google Scholar
• Teh BW, Brown C, Joyce T, et al. Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. Support Care Cancer. 2018;26:997–1003.
   PubMed Web of Science ®Google Scholar
• Lingaratnam S, Mellerick A, Worth LJ, et al. Feasibility of early discharge strategies for neutropenic fever: outcomes of a Victorian organisational readiness assessment and pilot. Intern Med J. 2013;43:979–986.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48:1042–1051.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Robin C, Alanio A, et al. Antifungal pre-emptive strategy for high-risk neutropenic patients: why the story is still ongoing. Clin Microbiol Infect. 2014;20(Suppl 6):27–35.
   PubMedGoogle Scholar
• Yuan W, Ren J, Guo X, et al. Preemptive antifungal therapy for febrile neutropenic hematological malignancy patients in China. Med Sci Monit. 2016;22:4226–4232.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018. DOI:10.1016/j.cmi.2018.01.002.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E. Multidrug-resistant bacteria: what is the threat? Hematology Am Soc Hematol Educ Program. 2013;2013:428–432.
   PubMedGoogle Scholar
• Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence. 2016;7:280–297.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Blau IW, Schwartz S, et al. Intensified strategies to control vancomycin-resistant enterococci in immunocompromised patients. Int J Hematol. 2007;86:158–162.
   PubMed Web of Science ®Google Scholar
• Valdezate S, Miranda C, Navarro A, et al. Clonal outbreak of ST17 multidrug-resistant Enterococcus faecium harbouring an Inc18-like: Tn1546plasmid in a haemo-oncology ward of a Spanish hospital. J Antimicrob Chemother. 2012;67:832–836.
   PubMed Web of Science ®Google Scholar
• O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015;8:217–230.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Castanheira M, Farrell DJ, et al. Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. J Antimicrob Chemother. 2016;71:3453–3458.
   PubMed Web of Science ®Google Scholar
• Zirakzadeh A, Gastineau DA, Mandrekar JN, et al. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008;41:385–392.
   PubMed Web of Science ®Google Scholar
• Scheich S, Lindner S, Koenig R, et al. Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. Cancer. 2018;124:286–296.
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee DG, Choi SM, et al. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. BMC Infect Dis. 2013;13:504.
   PubMed Web of Science ®Google Scholar
• Weisser M, Theilacker C, Tschudin Sutter S, et al. Secular trends of bloodstream infections during neutropenia in 15 181 haematopoietic stem cell transplants: 13-year results from a European multicentre surveillance study (ONKO-KISS). Clin Microbiol Infect. 2017;23:854–859.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Di Blasi R, Skert C, et al. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97:1717–1726.
   PubMed Web of Science ®Google Scholar
• Lisboa LF, Miranda BG, Vieira MB, et al. Empiric use of linezolid in febrile hematology and hematopoietic stem cell transplantation patients colonized with vancomycin-resistant Enterococcus spp. Int J Infect Dis. 2015;33:171–176.
   PubMed Web of Science ®Google Scholar
• Ng TM, Khong WX, Harris PNA, et al. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing enterobacteriaceae. PLoS ONE. 2016;11:e0153696.
   PubMed Web of Science ®Google Scholar
• Harris PNA, Tambyah PA, Lye DC, et al. MERINO trial investigators and the Australasian society for infectious disease clinical research network (ASID-CRN). Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320:984–994.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Royo-Cebrecos C, Abdala E, et al. Efficacy of β-Lactam/β-Lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-β-Lactamase-Producing enterobacteriaceae in hematological patients with neutropenia. Antimicrob Agents Chemother. 2017;61. pii:e00164-17.
   Web of Science ®Google Scholar
• Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, et al. Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum β-Lactamase-Producing enterobacteriaceae: results from the INCREMENT cohort. Clin Infect Dis. 2017;65:1615–1623.
   PubMed Web of Science ®Google Scholar
• Cometta A, Kern WV, de Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37:382–389.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005;5:431–439.
   PubMed Web of Science ®Google Scholar
• Robinson PD, Lehrnbecher T, Phillips R, et al. Strategies for empiric management of pediatric fever and neutropenia in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review of randomized trials. J Clin Oncol. 2016;34:2054–2060.
   PubMed Web of Science ®Google Scholar
• Ponraj M, Dubashi B, Harish BH, et al. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia. Support Care Cancer. 2018;26:3899–3908.
   PubMed Web of Science ®Google Scholar
• Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010;38:1773–1785.
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Picardi M, et al. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol. 2014;32:1463–1471.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): A retrospective cohort study. Lancet Infect Dis. 2017;17:726–734.
   PubMed Web of Science ®Google Scholar
• Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017;4:e573–e583.
   PubMed Web of Science ®Google Scholar
• Le Clech L, Talarmin JP, Couturier MA, et al. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study. Infect Dis (Lond). 2018;50:539–549.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Rozenberg-Arska M, Dekker AW. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clin Infect Dis. 1995;21:1300–1302.
   PubMed Web of Science ®Google Scholar
• Mokart D, Slehofer G, Lambert J, et al. De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med. 2014;40:41–49.
   PubMed Web of Science ®Google Scholar
• Orasch C, Averbuch D, Mikulska M, et al. Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. Clin Microbiol Infect. 2015;21:e25–e27.
   PubMed Web of Science ®Google Scholar
• Kroll AL, Corrigan PA, Patel S, et al. Evaluation of empiric antibiotic de-escalation in febrile neutropenia. J Oncol Pharm Pract. 2016;22:696–701.
   PubMed Web of Science ®Google Scholar
• Snyder M, Pasikhova Y, Baluch A. Early antimicrobial de-escalation and stewardship in adult hematopoietic stem cell transplantation recipients: retrospective review. Open Forum Infect Dis. 2017;4:ofx226.
   PubMed Web of Science ®Google Scholar
• Gustinetti G, Raiola AM, Varaldo R, et al. De-escalation and discontinuation of empirical antibiotic treatment in a cohort of allogeneic hematopoietic stem cell transplantation recipients during the pre-engraftment period. Biol Blood Marrow Transplant. 2018;24:1721–1726.
   PubMed Web of Science ®Google Scholar
• La Martire G, Robin C, Oubaya N, et al. De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome. Eur J Clin Microbiol Infect Dis. 2018;37:1931–1940.
   PubMed Web of Science ®Google Scholar
• Slobbe L, van der Waal L, Jongman LR, et al. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study. Eur J Cancer. 2009;45:2810–2817.
   PubMed Web of Science ®Google Scholar
• Micol JB, Chahine C, Woerther PL, et al. Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical? Clin Microbiol Infect. 2014;20:O453–O455.
   PubMed Web of Science ®Google Scholar
• Lima SSS, Nobre V, de Castro Romanelli RM, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol. 2016;95:1169–1176.
   PubMed Web of Science ®Google Scholar
• Haddad HE, Chaftari AM, Hachem R, et al. Procalcitonin guiding antimicrobial therapy duration in febrile cancer patients with documented infection or neutropenia. Sci Rep. 2018;8:1099.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Cordonnier C, Livermore DM, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013;98:1836–1847.
   PubMed Web of Science ®Google Scholar
• Jaffal K, Poissy J, Rouze A, et al. De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety. Ann Intensive Care. 2018;8:49.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–1402.
   PubMed Web of Science ®Google Scholar
• Chen K, Wang Q, Pleasants RA, et al. Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis. BMC Infect Dis. 2017;17:159.
   PubMed Web of Science ®Google Scholar
• Vento S, Cainelli F, Temesgen Z. Lung infections after cancer chemotherapy. Lancet Oncol. 2008;9:982–992.
   PubMed Web of Science ®Google Scholar
• Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397–2404.
   PubMed Web of Science ®Google Scholar
• Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol. 1999;17:796–805.
   PubMed Web of Science ®Google Scholar
• Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246:697–722.
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71:2405–2413.
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26.
   PubMed Web of Science ®Google Scholar
• Hentrich M, Schalk E, Schmidt-Hieber M, et al. Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the infectious diseases working party of the German society of hematology and medical oncology. Ann Oncol. 2014;25:936–947.
   PubMed Web of Science ®Google Scholar
• Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis. 1992;14:75–82.
   PubMed Web of Science ®Google Scholar
• Zeylemaker MM, Jaspers CA, van Kraaij MG, et al. Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2001;20:380–384.
   PubMed Web of Science ®Google Scholar
• Drawz SM, Papp-Wallace KM, Bonomo RA. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58:1835–1846.
   PubMed Web of Science ®Google Scholar
• Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16:603–616.
   PubMed Web of Science ®Google Scholar